The societal impact of cardiovascular disease is huge.
The societal impact of cardiovascular disease is huge. Based on current World Health Organisation (WHO) statistics, an estimated 17.9 million people die through CVD each year, approximately 30% of total global deaths. For those with advanced stage heart failure, or damaged hearts, implanting Mechanical Circulatory Support devices (MCS) are often their best hope for survival. MCS devices include technologies such as Left Ventricular Assist Devices (LVAD), which are attached to the heart to assist it in its function, through to Total Artificial Hearts (TAH), sophisticated pumps that replace the heart entirely.
As CVD has risen, so has the need to develop new, more sophisticated MCS devices that are smaller, more efficient, more reliable and more suited to modern lifestyles. The key elements of an MCS system could be classified as a portable power-supply, a controller, and a pump.
With 10 years of MCS development experience, specifically in MCS controller development, Hydrix has identified an industry need for a platform technology to enable MCS developers to focus on their core IP, the pump, while we assist with tools and platform technology to enable sophisticated control. Through a program of market insights and industry research, we have developed an innovative system called LUDO, a highly configurable pump controller platform, suitable for use throughout the development cycle, including early-stage lab testing, animal trials, first-in-human trials and commercial production.
Hydrix is a product innovation company developing FDA Class II and Class III medical devices for clients around the globe. Our unique team of designers, engineers, commercial and clinical & regulatory strategists combines to create market winning solutions that encompass financial, regulatory and clinical strategy.